Novo Nordisk A/S ( NVO ) shareholders have had a 2025, to forget as the stock has tumbled due to increased competition, pressure from the U.S. government to lower drug prices, and a pared-back financial outlook. While the currentTo follow me click the "Follow" button! (Easy right?) Hi there, thanks for coming to my profile page! My name is Kumquat Research (but you can call me Jeremy) and I've been writing for Seeking Alpha on and off for going on ten years now, beginning with my inaugural published piece d ...